Brain-controlled art app to help with depression symptoms
Developping a a Brain-controlled Art App to Ease Residual Symptoms of Depression
This study is testing whether a brain-controlled art app can help people aged 25 to 65 with lingering depression symptoms feel better after 10 neurofeedback sessions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 22 (estimated) |
| Ages | 25 Years to 65 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Locations | 1 site (Besançon) |
| Trial ID | NCT06098469 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of 10 neurofeedback sessions on patients with residual symptoms of depression who are in partial remission. Participants will engage with a brain-controlled art application designed to ease their depressive symptoms. The study focuses on individuals aged 25 to 65 who have a specific score range on the MADRS scale, indicating their level of depression. The approach aims to leverage neurofeedback as a novel intervention for enhancing mental health outcomes.
Who should consider this trial
Good fit: Ideal candidates are right-handed individuals aged 25 to 65 with a diagnosis of major depressive episode in remission and a MADRS score between 14 and 22.
Not a fit: Patients with other psychiatric disorders or significant cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could provide a new therapeutic option for patients struggling with residual depressive symptoms.
How similar studies have performed: While neurofeedback has been explored in various contexts, this specific application in conjunction with an art app is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects aged 25 to 65 included * Information and signed informed consent * Patients with a diagnosis of major depressive episode in remission * MADRS score between 14 and 22 * Patients with residual symptoms as assessed by MADRS items * No cognitive impairment. * Right-handed Exclusion Criteria: * Subjects with legal incapacity or limited legal capacity * Subjects unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator * Pregnant women * Subjects in the exclusion period of another study or is on the "national volunteer list". * Subjects with another psychiatric pathology (bipolar mood disorder, psychosis, obsessive-compulsive disorder, addictive pathology, schizophrenia) * Subjects under a protective measure such as guardianship or safeguard of justice.
Where this trial is running
Besançon
- CHU Besançon — Besançon, France (Recruiting)
Study contacts
- Principal investigator: Emmanuel HAFFEN, MD PhD — CHU de Besançon
- Study coordinator: Karine CHARRIERE, PhD
- Email: kcharriere@chu-besancon.fr
- Phone: +333 81218999
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.